TopLink BioTherapeutics: Pioneering Innovation in Autoimmune Disease Treatment with CDE- and FDA-Approved Novel Drug TollB-001

In the 1990s, scientists first discovered Toll-like receptors (TLRs), a critically important protein in the human immune system. As pattern recognition receptors, TLRs are capable of recognizing a broad spectrum of pathogens and activating immune responses, playing a pivotal role in both innate and adaptive immunity.

In 2011, two scientists—Bruce Beutler and Jules Hoffmann—jointly received the Nobel Prize in Physiology or Medicine for their discoveries concerning “the activation of innate immunity.” The discovery of Toll-like receptors is hailed as one of the most significant breakthroughs in biology during the 20th century. As research into and understanding of Toll-like receptor signaling mechanisms in autoimmune diseases (hereinafter referred to as “autoimmune diseases”) have deepened, Toll-like receptors have become a focal point for therapeutic development, prompting numerous companies to strategically position themselves around this target.

In this context,Beijing Tuoling Botai Biotechnology Co., Ltd. (hereinafter referred to as “Tuoling Botai”), an innovative enterprise dedicated to the research and development of first-in-class novel therapeutics for autoimmune diseases, was established.. Tuoling Botai is dedicated to providing patients with innovative therapies that modulate the human immune response, addressing the pain points in the global market for immunomodulatory drugs.。

Leveraging nearly two decades of accumulated expertise in the mechanisms of immune regulation and the development of immunomodulatory drugs, TopAll Biotherapeutics has established Toll-like receptor (TLR)-mediated innate immune regulation as its core technology platform. The company has made groundbreaking discoveries of novel immune regulatory mechanisms and differentiated small-molecule new drugs, and has built a robust pipeline of drug candidates targeting indications such as rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus.

Among them,TollB-001, a Class 1.1 novel small-molecule drug for the treatment of rheumatoid arthritis, received approval from both the FDA and the CDE in 2023 to commence clinical trials ahead of schedule. TollB-001 is the first target-specific small-molecule drug among global competitors with the same target to enter the clinical stage, and it is currently in Phase I clinical trials.。

Founded in 2020, Top Biotech is dedicated to the research and development of innovative medicines that benefit patients worldwide, leveraging its team’s nearly two decades of research expertise and addressing unmet clinical needs.

Professor Hang Yin, the company’s founder, is an internationally renowned immunology expert with nearly two decades of dedicated experience in novel drug research and development.Prior to founding the company, Professor Hang Yin served as a tenured professor in the Department of Chemistry and Biochemistry at the University of Colorado, where he conducted pioneering research on Toll-like receptors. After returning to China in 2013, Professor Yin joined Tsinghua University and established his research team. He previously served as the inaugural Vice Dean of the School of Pharmaceutical Sciences at Tsinghua University and currently serves as a member of the University Academic Committee.

Since the initiation of research on Toll-like receptors,Professor Yin Hang collaborated with Dr. Li Jing, Chief Physician in the Department of Rheumatology and Immunology at Peking Union Medical College Hospital, to jointly advance research on Toll-like receptors and autoimmune diseases, publishing multiple high-quality academic articles.Dr. Li Jing holds a Ph.D. from Peking Union Medical College. She currently serves as a Young Committee Member of the Rheumatology and Clinical Immunology Branch of the Chinese Medical Doctor Association, as well as Secretary and Committee Member of the Vasculitis Study Group. Dr. Li has overseen multiple clinical research projects for innovative drugs targeting diseases such as rheumatoid arthritis and lupus erythematosus, several of which have received marketing approval. Leveraging her extensive clinical experience and long-standing collaborative relationships, Dr. Li has provided professional guidance and support in the clinical application of small-molecule Toll-like receptor (TLR) drugs.

Dr. Gao Meng, Co-founder and General Manager of TopAll Biotech, has extensive research experience in the field of Toll-like receptors.Dr. Gao Meng holds dual degrees in Chemistry and Economics from Renmin University of China. She later joined Professor Yin Hang’s research group at Tsinghua University, where she earned her Ph.D. With over a decade of experience in new drug research and development, she has published multiple SCI papers and filed numerous invention patents. Notably, she was listed on Cyzone’s 2024 List of Entrepreneurial Pioneers Under 35. Her accolades include serving as an expert reviewer for Beijing Municipal Science and Technology Projects and as an expert in the transformation of scientific and technological achievements in medicine and health in Beijing; receiving the First Prize of the Chinese Pharmaceutical Association Science and Technology Award; being named a Winner of the Zhongguancun U30 2023; honored as the 2023 VB-Link Award Outstanding Young Scientist in Translation; and recognized as one of Cyzone’s 2024 Most Worth-Watching Female Entrepreneurs.

Following its establishment, Toplead Biotech rapidly assembled a translational team with complementary expertise, recruiting several professionals from the industry with extensive experience in commercialization to support the efficient translation of innovative drugs from candidate optimization and druggability studies through preclinical research to clinical trials.

In addition,TopLead BioTech collaborates with renowned institutions and leading enterprises such as Tsinghua University and Baidu., leveraging the state-of-the-art technology platform of the Tsinghua University Pharmaceutical Technology Center and Baidu’s PaddleHelix biological computing platform, we continue to develop new projects and novel drug molecules, continuously enriching our downstream R&D pipeline. We are strategically positioning ourselves across multiple therapeutic areas with significant clinical needs in immunological diseases and rare diseases, while simultaneously implementing comprehensive patent protection and strategic layout for small-molecule drugs, covering major pharmaceutical R&D countries and regions worldwide.

Since 2007, Professor Hang Yin has conducted extensive research on the mechanisms and small-molecule modulators of Toll-like receptors (TLRs). He has identified 10 distinct human TLRs and established a cell-based drug screening platform to develop specific, precision-targeted small-molecule drug candidates. To date, he has published more than 150 papers, which have been cited over 20,000 times. Notably, his reports on small-molecule modulators targeting TLR1/2, TLR3, TLR5, and TLR8 are the first of their kind globally. In particular, his research on TLR8 has uncovered groundbreaking novel regulatory mechanisms and drug-binding pockets, providing fresh perspectives for research in related fields.

Currently, Tuoling Botai’s flagship launchTollB-001 is a Class 1.1 oral small-molecule novel drug targeting Toll-like receptor 8, designed for the treatment of autoimmune diseases with significant clinical unmet needs, such as rheumatoid arthritis (RA) and systemic sclerosis.Notably,TollB-001 is the first small-molecule drug with target selectivity to enter clinical development globally among drugs targeting the same locus, and it features a differentiated innovative mechanism of action.。

Preclinical studies show that,TollB-001 effectively reduces disease severity in cynomolgus monkeys with spontaneous rheumatoid arthritis (a natural disease model), demonstrating significant in vivo efficacy. In both animal and human studies, TollB-001 exhibits an excellent safety profile in vivo, holding promise for addressing the limitations of existing therapies, such as inadequate response rates and significant side effects.Notably, TollB-001 features stable physicochemical properties, a simple synthesis process, and controllable impurities, thereby enabling scalable production with controlled costs. Furthermore, TollB-001 is designed for oral administration with once-daily dosing, significantly improving patient compliance.

Currently, TollB-001 is undergoing Phase I clinical trials to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and food effects in humans. Existing data indicate that TollB-001 demonstrates excellent safety and efficacy.Phase I clinical trials are scheduled to conclude by the end of 2024, with Phase II clinical trials expected to commence in early 2025.。

In addition to targeting rheumatoid arthritis, TollB-001 is also being developed for the treatment of systemic sclerosis. Systemic sclerosis is a rare disease with no currently effective clinical therapies available. Preclinical studies have demonstrated that TollB-001 exhibits highly significant in vivo efficacy. The drug is currently under regulatory review for clinical trial approval and will be rapidly advanced into clinical development.

Focusing on the 10 distinct human Toll-like receptors, TopAll Biotech has developed multiple specific small-molecule drug candidates for the treatment of various autoimmune diseases.

For example, TopAll Biotech has developed the TollB-002 pipeline for systemic lupus erythematosus.TollB-002 is currently in the preclinical research stage. Preclinical data indicate that TollB-002 demonstrates best-in-class efficacy in animal models. An Investigational New Drug (IND) application will be filed this year to initiate clinical trials.. In addition, the company has established a diverse pipeline of investigational products, with the majority expected to enter clinical trials between 2024 and 2025.

With outstanding team strength and multiple milestone achievements,Tuoling Botai has garnered significant investor interest, completing its angel and Series A funding rounds in quick succession, with cumulative financing nearing RMB 200 million.。

Since its establishment, TopLead BioTech has received numerous honors and awards. For instance, TopLead BioTech won the highest award at the National Disruptive Technology Innovation Competition Finals organized by the Ministry of Science and Technology, the Excellent Enterprise Award at the China Innovation and Entrepreneurship Competition (National Finals) as well as the Second Prize in Beijing, the Third Prize at the HICOOL 2023 Global Entrepreneurship Competition, and was included in the “List of 100 New Technologies and Products” at the Zhongguancun Forum. It was also recognized as a Deloitte “2023 China Pharmaceutical and Health Rising Star.” Furthermore, the company has obtained certifications including National Science and Technology-based Small and Medium-sized Enterprise (by the Ministry of Science and Technology), Beijing Specialized, Refined, Differential, and Innovative (SRDI) SME, Beijing Innovative SME, Zhongguancun High-tech Enterprise, and Beijing Intellectual Property Pilot Unit.

According to Frost & Sullivan, the market size of autoimmune drugs in China is expected to reach approximately $23 billion by 2030. Autoimmune diseases have now become the second largest disease category after cancer, and the corresponding drug market has emerged as the second largest therapeutic area. Currently, numerous companies have entered this multi-billion-dollar market, laying out over a hundred new drug pipelines for autoimmune diseases, potentially leading to a fiercely competitive landscape akin to a "battle of hundreds of drugs."

In response, Dr. Gao Meng said, “Robust research accumulation, close integration with clinical practice, advanced R&D platforms and teams, as well as an innovative and differentiated new drug pipeline are the core advantages that enable Topall Biotech to break through market competition.。”

Currently, TopLead Biotech has established a patent moat, having independently filed 12 invention patents and secured exclusive licenses for 13 patents, thereby achieving differentiated innovation at the source of drug development.

Looking ahead, Dr. Gao Meng stated, “Tuoling Botai is accelerating the clinical translation and commercialization of its drug candidates, with the aim of developing effective, safe, cost-controllable, and user-friendly medicines to fill market gaps and address unmet clinical needs.”。

As the “hundred-drug war” in China’s domestic autoimmune disease market is about to begin, we look forward to Tuoling Botai accelerating the R&D of new autoimmune drugs, bringing more innovative therapies to the industry and ultimately benefiting more patients.